Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer

Cancer

Volumn 121, Issue 19, 2015, Pages 3444-3451

  Watkins, Jack L ^a   Thaker, Premal H ^b   Nick, Alpa M ^a   Ramondetta, Lois M ^a   Kumar, Sanjeev ^c   Urbauer, Diana L ^a   Matsuo, Koji ^d   Squires, Kathryn C ^b   Coleman, Robert L ^a   Lutgendorf, Susan K ^e,f   Ramirez, Pedro T ^a   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d MERCY MEDICAL CENTER   (United States)

^e University of Iowa   (United States)

^f UNIVERSITY OF IOWA   (United States)

Author keywords

beta blockers; nonselective; ovarian cancer; selective; survival

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; COMORBIDITY; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; DRUG USE; FEMALE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TOTAL QUALITY MANAGEMENT; UTERINE TUBE CARCINOMA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84941941304     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29392     Document Type: Article

References (19)

1. Lutgendorf SK, Cole S, Costanzo ES, et al., Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res. 2003; 12: 4514-4521.
2. Sood AK, Bhatty R, Kamat AA, et al., Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res. 2006; 12: 369-375.
3. Thaker PH, Han LY, Kamat AA, et al., Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006; 12: 939-944.
4. Tang J, Li Z, Lu L, Cho CH,. β-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy. Semin Cancer Biol. 2013; 23 (6 pt B): 533-542.
5. Diaz ES, Karlan BY, Li AJ,. Impact of beta blockers on epithelial ovarian cancer survival. Gynecol Oncol. 2012; 127: 375-378.
6. Eskander R, Bessonova L, Chiu C, et al., Beta blocker use and ovarian cancer survival: a retrospective cohort study. Gynecol Oncol. 2012; 127 (suppl 1): S21.
7. Johannesdottir SA, Schmidt M, Phillips G, et al., Use of β-blockers and mortality following ovarian cancer diagnosis: a population-based cohort study. BMC Cancer. 2013; 13: 85.
8. IMS Institute for Healthcare Informatics. Declining medicine use and costs: for better or worse? A review of the use of medicines in the United States in 2012. Available at: http://www.imshealth.com/vgn-ext-templating/v/index.jsp?vgnextoid=5b21ee0a8e631410VgnVCM1000007619ca2RCRD. Accessed April 1, 2014.
9. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
10. Cox DR,. Regression models and life tables. J R Stat Soc B. 1972; 34: 187-220.
11. Kleinbaum DG,. Survival Analysis-A Self-Learning Text. New York: Springer-Verlag Publishers; 1996.
12. Heitz F, duBois A, Harter P, et al,; AGO Study Group; NCIC-CTG Study Group; EORTC-GCG Study Group. Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORT-GCG. Gynecol Oncol. 2013; 129: 463-466.
13. Sood AK, Armaiz-Pena GN, Halder J, et al., Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest. 2010; 120: 1515-1523.
14. Nagaraja AS, Sadaoui NC, Lutgendorf SK, Ramondetta LM, Sood AK,. β-blockers: a new role in cancer chemotherapy? Expert Opin Investig Drugs. 2013; 22: 1359-1363.
15. Sloan EK, Priceman SJ, Cox BF, et al., The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 2010; 70: 7042-7052.
16. Lee JW, Shahzad MM, Lin YG, et al., Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res. 2009; 15: 2695-2702.
17. Lindgren ME, Fagundes CP, Alfano CM, et al., Beta-blockers may reduce intrusive thoughts in newly diagnosed cancer patients. Psychooncology. 2013; 22: 1889-1894.
18. ClinicalTrials.gov. Therapeutic targeting of stress factors in ovarian cancer patients. Available at: clinicaltrials.gov/ct2/show/NCT01308944. Accessed April 1, 2014.
19. ClinicalTrials.gov. Beta-blocker/ovarian. Available at: clinicaltrials.gov/ct2/show/NCT01504126. Accessed April 1, 2014.